Breast Cancer Aotearoa Coalition and Breast Cancer Foundation NZ have made a strongly worded and evidence-based joint submission to PHARMAC requesting that funding for Perjeta (pertuzumab) be extended to all people with HER2-positive advanced breast cancer.
The submission was made to the Cancer Treatment Sub-committee (known as CaTSoP). At its September meeting, CaTSoP will consider applications for funding for the following breast cancer medicines – Perjeta, Kadcyla, Ibrance, Abraxane, Faslodex.
Attached is the joint submission sent to CaTSoP and the poster referred to in the letter.
24 July 2018
Article Type
